https://www.techtarget.com/pharmalifesciences/news/366641022/Novo-claims-edge-over-Lillys-newly-approved-GLP-1-pill-in-cross-study 2026-04-02 TechTarget en Novo claims edge over Lilly's newly approved GLP-1 pill in cross study https://www.techtarget.com/pharmalifesciences/news/366640790/Eli-Lilly-expands-Insilico-pact-with-275B-AI-drug-discovery-deal 2026-03-30 TechTarget en Eli Lilly expands Insilico pact with $2.75B AI drug discovery deal https://www.techtarget.com/pharmalifesciences/news/366640757/GLP-1-drugs-show-promise-in-managing-chronic-migraines 2026-03-25 TechTarget en GLP-1 drugs show promise in managing chronic migraines https://www.techtarget.com/pharmalifesciences/news/366640550/Boehringer-Ingelheim-adds-3-drugs-to-TrumpRx 2026-03-24 TechTarget en Boehringer Ingelheim adds 3 drugs to TrumpRx https://www.techtarget.com/pharmalifesciences/news/366640348/Lillys-triple-G-agonist-shows-unique-promise-in-late-stage-diabetes-trial 2026-03-19 TechTarget en Lilly's triple-G agonist shows unique promise in late-stage diabetes trial https://www.techtarget.com/pharmalifesciences/news/366640421/Roches-new-NVIDIA-deal-locks-in-the-industrys-largest-hybrid-cloud-AI-factory 2026-03-18 TechTarget en Roche's new NVIDIA deal locks in the industry's 'largest hybrid-cloud AI factory' https://www.techtarget.com/pharmalifesciences/news/366640365/Structures-GLP-1-pill-shows-injectable-like-efficacy-in-a-mid-stage-obesity-study 2026-03-17 TechTarget en Structure's GLP-1 pill shows 'injectable-like efficacy' in a mid-stage obesity study https://www.techtarget.com/pharmalifesciences/news/366639951/Lilly-warns-of-impurities-in-compounded-tirzepatide-containing-B12 2026-03-12 TechTarget en Lilly warns of impurities in compounded tirzepatide containing B12 https://www.techtarget.com/pharmalifesciences/news/366639953/Regenerons-GLP-1-GIP-obesity-drug-succeeds-in-late-stage-trial 2026-03-09 TechTarget en Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial https://www.techtarget.com/pharmalifesciences/news/366639853/Roche-Zealand-tout-the-tolerability-of-their-amylin-obesity-drug 2026-03-06 TechTarget en Roche, Zealand tout the tolerability of their amylin obesity drug https://www.techtarget.com/pharmalifesciences/news/366639663/Lilly-rolls-out-Employer-Connect-to-close-obesity-coverage-gaps 2026-03-05 TechTarget en Lilly rolls out Employer Connect to close obesity coverage gaps https://www.techtarget.com/pharmalifesciences/news/366639581/FDA-continues-crackdown-on-DTC-advertising-for-compounded-GLP-1s 2026-03-04 TechTarget en FDA continues crackdown on DTC advertising for compounded GLP-1s